In September 2021, the FDA accelerated approval of mobocertinib for metastatic NSCLC with EGFR exon 20 insertion mutations following the initial results of phase I/II study 101, an international, non-randomized, open-label, multicohort clinical trial (NCT02716116). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.